Juan María Beitia Mazuecos

Juan María Beitia Mazuecos

Auto-generated profile, based on publicly available information

Juan María Beitia Mazuecos

Unidad de Alergología Hospital Universitario de Fuenlabrada Madrid Spain

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 August 2026 in Clinical and Translational Allergy
Verified
Journal Article
Open access
EGEloína González‐Mancebo
Eloína González‐Mancebo
JMJuan María Beitia Mazuecos
Juan María Beitia Mazuecos
APAna I Tabar Purroy
Ana I Tabar Purroy
MGMar Gandolfo‐Cano
Mar Gandolfo‐Cano
AIAdriana Izquierdo-Dominguez
Adriana Izquierdo-Dominguez
AGAlba Juárez Guerrero
Alba Juárez Guerrero
Background: Allergic rhinitis, conjunctivitis and asthma are prevalent IgE‐mediated respiratory diseases that frequently coexist and impair quality of life. Allergen immunotherapy (AIT) has clinical benefits and potential disease‐modifying effects. Until recently, standardised definitions of disease control and remission were lacking in routine clinical practice, particularly for allergic rhinitis and conjunctivitis. This study aimed to propose preliminary definitions of control and remission in patients receiving AIT and to assess expert consensus using the Delphi methodology. Methods: A scientific committee developed a survey based on a literature review and expert input, addressing symptoms, medication use, quality of life, exacerbations and tools for objective and subjective assessment. Forty allergists participated in a two‐round Delphi study. Consensus was predefined as ≥ 70% agreement on a 9‐point Likert scale. Results: Consensus was achieved for all items after two rounds. The panel agreed on proposed definitions of disease control and clinical remission for allergic rhinitis, conjunctivitis and asthma in the context of AIT, integrating symptom severity, medication use, validated questionnaires and objective measures. Conclusions: This study presents preliminary expert‐consensus definitions of control and remission in allergic rhinitis, conjunctivitis and asthma in patients undergoing AIT. These definitions should not be interpreted as validated clinical criteria or endpoints. As a preliminary proposal, they aim to provide a structured approach for assessing treatment response in clinical practice by integrating symptom burden, medication use, patient‐reported outcomes and objective measures. They should be regarded as an initial conceptual step, and further prospective studies are needed to validate these criteria and confirm their relevance, feasibility and applicability.